NewTimeSpace News: Shanghai Henlius Biotech Co., Ltd. (02696.HK) announced that the global multicenter Phase 3 clinical study of HLX04-O, a recombinant anti-VEGF humanized monoclonal antibody injection for the treatment of wet age-related macular degeneration (wAMD), has reached its primary endpoint. The trial results demonstrated that the mean change in best corrected visual acuity (BCVA) from baseline at Week 36 and Week 48 in the HLX04-O group was non-inferior to that of the ranibizumab group, with a favorable safety profile.
NewTimeSpace News: On June 16, 2026, RoboSense(02498.HK) remained weak in afternoon trading. As of 15:30, its intraday price stood at HK$25.96, down 7.55%. The Peacock chip will officially launch mass production within 2026.
NewTimeSpace (newtimespace.com) News: On June 16, 2026, the share price of Xiaomi-W (01810.HK) continued to fluctuate and weaken. As of 1:29 PM, the company was quoted at HK$25.780, down 1.83%.
NewTimeSpace News: Fusen Pharmaceutical Company Limited (01652.HK) announced that the marketing application for Piracetam Injection developed by its wholly-owned subsidiary Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Co., Ltd. has been approved by the National Medical Products Administration (NMPA). The product is indicated for memory impairment and mild to moderate cerebral dysfunction caused by acute and chronic cerebrovascular diseases, brain trauma and toxic encephalopathy, and also for mental retardation in children. Piracetam Injection is a Class B drug covered by the National Medical Insurance Catalogue, with domestic sales exceeding RMB250 million in 2025.
NewTimeSpace (newtimespace.com) News, On June 16, 2026, large model concept stocks such as Zhipu (2513.HK) and Mininglamp Technology (2718.HK) strengthened during morning trading. As of 10:08 AM, Mininglamp Technology (2718.HK) was quoted at HK$247.600, up 2.91%. Choice data shows that Mininglamp Technology's share price has recently delivered a strong rally, with its cumulative gain over the past five days exceeding 35% as of now.
NewTimeSpace News: CSPC Pharmaceutical Group announced on June 15 that its self-developed Albumin-bound Paclitaxel for Injection (II) has been approved for launch by the National Medical Products Administration.
On June 15, Hong Kong stocks fluctuated higher as the AI and semiconductor supply chains erupted across the board. ZHIPU AI skyrocketed over 32% following the full release and imminent open-sourcing of its GLM-5.2 model, driving a market revaluation of domestic LLMs, while semiconductor and AI hardware equities like Hua Hong and Lenovo surged. Industry dynamics highlighted a stark divergence: the US Commerce Department imposed strict export controls on Anthropic's latest models, forcing a global access suspension, whereas ZHIPU AI championed accessibility by fully opening its most powerful model. Concurrently, XUNCE forged strategic alliances with three major domestic GPU manufacturers to develop integrated hardware-software solutions tailored for vertical industries.
NewTimeSpace News: On June 15, 2026, XPENG-W(09868.HK) trended lower amid afternoon volatility. As of 15:23, the stock was quoted at HK$55.75, down 3.38%. Its first mass-produced Robotaxi rolled off the production line in Guangzhou on May 18, 2026, with demonstration operations expected to launch in the second half of 2026.
NewTimeSpace (newtimespace.com) News: On June 15, 2026, the semiconductor concept sector in the Hong Kong stock market continued to strengthen, with the share price of ASMPT (00522.HK) pulling up substantially. As of 1:44 PM, the company's share price was quoted at HK$199.300, up 8.97%.
NewTimeSpace (newtimespace.com) News: The robotics concept sector surged as UBTECH (09880.HK) opened higher and rallied on June 15. As of 1:24 PM, the company's share price was quoted at HK$113.400, up 6.18%.
PATEO (2889.HK) and Mininglamp Technology (2718.HK) signed a strategic cooperation framework agreement. The two parties will integrate Mininglamp Technology's capabilities in AI large models, AI Agent suites, and precision marketing withPATEO's resources in edge-side hardware entry points, AI computing power infrastructure, and in-vehicle application scenarios. Together, they will build an "AI × Vehicle × User Demand" chain platform.
NewTimeSpace News: Beijing Zhipu Huazhang Technology Co., Ltd. (02513.HK) announced that it has launched its new-generation flagship model GLM-5.2. The model features a 1M long context and keeps leading performance in long-horizon tasks. It will be open-sourced under the MIT License. The model is expected to increase the call volume of the company's open platform and API business in the future.
NewTimeSpace News: Genscript Biotech Corporation (01548.HK) announced that its associate company Legend Biotech presented the first proof-of-concept clinical data of LB2501, an investigational in-vivo CD19/CD20 dual-target CAR-T cell therapy, for the treatment of relapsed/refractory B-cell non-Hodgkin's lymphoma at the 2026 EHA Annual Meeting. At higher dose levels, the overall response rate reached 100% and the complete response rate stood at 83.3%, with all responses sustained. No dose-limiting toxicity, serious adverse events or immune effector cell-associated neurotoxicity syndrome were reported.
NewTimeSpace News: Simcere Pharmaceutical Group Limited (02096.HK) announced that SIM0689, a self-developed PD-1/VEGF-targeted bispecific antibody, has obtained the clinical trial approval notice issued by the National Medical Products Administration. Clinical trials for advanced solid tumors are planned. By relieving tumor-induced immune suppression and inhibiting angiogenesis, SIM0689 has demonstrated prominent anti-tumor efficacy even at low doses in multiple humanized mouse efficacy models.
NewTimeSpace News: Mabwell (Shanghai) Bioscience Co., Ltd. (02493.HK) announced that the Investigational New Drug (IND) application for 6MW5311 Injection in hematologic malignancies (acute myeloid leukemia, chronic myelomonocytic leukemia, and multiple myeloma) has been officially approved by the U.S. FDA. 6MW5311 is the world’s first TCE innovative drug authorized for clinical development targeting LILRB4/CD3.
NewTimeSpace News: Akeso, Inc. (09926.HK) announced that Qiyoukang® (gumokimab, AK111), a novel humanized anti-IL-17 antibody independently developed by the company, has been approved by the National Medical Products Administration (NMPA) for the treatment of moderate-to-severe plaque psoriasis. Key Phase III data showed a 12-week PASI 75 response rate of 94.6% and a PASI 100 (complete skin clearance) rate of 47.7%; the 52-week PASI 100 rate reached 68.9% with a favorable safety profile.
